Buscopan® Injectable Solution
Buscopan® starts acting to relieve colic immediately. Colic relief was noted within 30 minutes in 88 percent of cases studied.1 That’s relief you know you can trust when your horse is in pain.
BUSCOPAN is indicated for the control of abdominal pain (colic) associated with spasmodic colic, flatulent colic and simple impactions in horses.
As the only FDA-approved antispasmodic for use in horses, BUSCOPAN works to relax the gastrointestinal smooth muscles and control pain associated with spasmodic colic. It gets right to the source of pain to relieve your horse.
Important Safety Information: BUSCOPAN's major side effect is a transient elevated heart rate. In clinical studies, administration of BUSCOPAN resulted in an increased average heart rate of 30 percent during the first five minutes, and by 30 minutes post treatment, the heart rate did not differ from its pretreatment value. Therefore, heart rate cannot be used as a valid indicator of pain severity for 30 minutes after injection.
Within 5–10 minutes, most horses will start responding to treatment. By 30 minutes, most horses will be relieved of painful colic spasms.1 Studies have shown that 88 percent of colic horses evaluated were judged by veterinarians to be successfully relieved of colic spasms within 30 minutes.1
Behavioral-attitude scores of “alert/calm” improved from just 13 percent prior to treatment to 67 percent at 15 minutes post treatment and 73 percent at 30 minutes post treatment.1 Total colic scores, based on a pretreatment colic examination and evaluation of colic signs, decreased from 6.5 pretreatment to 2.4 at 15 minutes post treatment, and went down to ascore of 2.1 at 30 minutes post treatment.1
Important Safety Information: Buscopan should not be used in impaction colics associated with ileus, or in horses with glaucoma. BUSCOPAN effects may be potentiated by use with other anticholinergic drugs. For intravenous use only. Safe use in nursing foals, pregnant or lactating mares has not been established.
1. FOI Summary, NADA 141-228